Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Zelboraf
|
| gptkbp:chemicalFormula |
small molecule
C23H18ClF2N3O |
| gptkbp:clinicalTrials |
Phase III
monotherapy_or_in_combination_with_cobimetinib |
| gptkbp:contraindication |
pregnancy
hypersensitivity reactions squamous cell carcinoma lactation hypersensitivity to vemurafenib keratoacanthoma |
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:endOfLife |
about 57 hours
|
| gptkbp:established |
gptkb:Daiichi_Sankyo
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:hasPopulation |
children
adults |
| https://www.w3.org/2000/01/rdf-schema#label |
Vemurafenib
|
| gptkbp:impact |
until disease progression
|
| gptkbp:interactsWith |
CYP3A4
CYP2C9 |
| gptkbp:is_monitored_by |
liver function tests
complete blood count skin examination |
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:mandates |
unresectable or metastatic melanoma
|
| gptkbp:marketedAs |
Zelboraf
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:packaging |
bottle
|
| gptkbp:patentStatus |
patented
|
| gptkbp:releaseYear |
2011
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
risk of infection
risk of liver toxicity risk of severe skin reactions risk of gastrointestinal perforation risk of QT prolongation risk of cardiac events risk of eye disorders risk of new malignancies |
| gptkbp:sideEffect |
fatigue
nausea joint pain skin rash photosensitivity |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
BRAF V600E mutation
|
| gptkbp:triggerType |
BRAF inhibitor
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:waterManagement |
urine
|